CTRI/2016/08/007163已完成4 期
A prospective,randomized, comparative study of safety and efficacy of pregabalin, duloxetine, amitriptyline and pregabalin plus amitriptyline in neuropathic pain in a tertiary care hospital in West Bengal
Dr Sourav Chakrabarty0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •(1)Diagnosed by consultant neurologist as having neuropathic pain.
- •(2)Scoring >=4 at DN4 Neuropathic pain diagnostic questionnaire
- •(3)Scoring >=4 at Numeric pain rating scale at baseline presentation.
- •(4)Age group 18-75 yrs.
排除标准
- •(1)Known serious spinal disease/bony deformity/vertebral fracture
- •(2)Abnormal renal function test.
- •(3)Cardiac conduction defect.
- •(4)Known allergy to any of the study medication.
- •(5)Benign Hyperplasia of prostate or H/O urinary retention.
- •(6)Pregnant& lactating mother.
- •(7)Patients taking MAO inhibitors.
- •(8)Inflammatory/Rheumatologic disorder.
- •(9)Suicidal tendency.
研究者
相似试验
已完成
4 期
A clinical study to see the effects of two different drugs, in patients undergoing laser for angle closure glaucomaCTRI/2017/12/010922Aravind eye hospital152
已完成
不适用
to find the safety and effect of dexmeditomedine and propofol given in sleeping dose in patients on breathing machine.CTRI/2018/07/014924okmanya Tilak municipal generalhospital and Medical college60
进行中（未招募）
1 期
A Randomised, Double-Blind Study Comparing the Safety and Efficacy of Etanercept with Sulphasalazine in Subjects with Ankylosing Spondylitis - ASCENDEUCTR2005-001549-41-ESWyeth Research Division of Wyeth Pharmaceuticals Inc525
进行中（未招募）
1 期
A Randomised, Double-Blind Study Comparing the Safety and Efficacy of Etanercept with Sulphasalazine in Subjects with Ankylosing Spondylitis - ASCENDEUCTR2005-001549-41-IEWyeth Research Division of Wyeth Pharmaceuticals Inc540
进行中（未招募）
不适用
A Randomised, Double-Blind Study Comparing the Safety and Efficacy of Etanercept with Sulphasalazine in Subjects with Ankylosing Spondylitis - ASCENDEUCTR2005-001549-41-DKWyeth Research Division of Wyeth Pharmaceuticals Inc540